Optimized Basement Membrane Extracts for Organoid Growth and Xenograft Models
AMSBIO announces the availability of two new formulations of Basement Membrane Extract (BME) known as Cultrex BME 2 (organoid growth matrix) and Cultrex BME 3 (xenograft/tumorgraft matrix).
The new products have been developed to address the heterogeneous nature of tissue and organ micro-environments that not only arise from organ specific stromal cells, growth factors, proteoglycans, and protein composition but also from the stiffness or tensile strength of the BME. Many studies have shown that there is a relationship between abnormal tensile strength and both cancer progression and fibrotic tissues. It is both the chemical and physical properties of the BME that are responsible for the mechanical and biological properties of tissues and organs. It was in light of this heterogeneity that Cultrex BME 2 and Cultrex BME 3 were developed.
BME 2 is based upon a proprietary formulation that is higher in tensile strength than original Matrigel or Cultrex BME. This growth factor reduced product is recommended for organoid growth applications including 3D cell culture from stem cells. By comparison, BME 3 has been developed to be physiologically aligned with the in vivo tumour environment and is recommended for xenografts, tumorgrafts and other in vivo applications.
Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma. Basement membranes are degraded and regenerated during development and wound repair. They not only support cells and cell layers, but they also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. Basement membranes provide major barriers to invasion by metastatic tumour cells. Cultrex BME is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumours. The extract gels at 37 °C to form a reconstituted basement membrane. The major components of BME include laminin, collagen IV, entactin, and heparin sulphate proteoglycan. BME can be used for growth promotion or for the differentiation of precursor cells, under a variety of cell culture conditions, involving primary epithelial, endothelial and smooth muscle cells. BME has also been employed in cell attachment, neurite outgrowth, angiogenesis assays, in vitro cell invasion and in vivo tumorigenicity assays.
For further information on Cultrex BME 2 and Cultrex BME 3 please visit http://www.amsbio.com/
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance